Clinical Trial Update: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for trastuzumab deruxtecan (Enhertu) in HER2-expressing tumors, including bladder, biliary tract, cervical, endometrial, ovarian…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Bladder Cancer
• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING